Diseases [C] » Nutritional and Metabolic Diseases [C18] » Metabolic Diseases » DNA Repair-Deficiency Disorders
Description
Disorders resulting from defective DNA REPAIR processes or the associated cellular responses to DNA DAMAGE. MeSH
Hierarchy View
Subtype Terms (11)
Ataxia Telangiectasia
29 drugs (27 approved, 2 experimental)
Cockayne Syndrome
1 approved drug
Colorectal Neoplasms, Hereditary Nonpolyposis
23 drugs (17 approved, 6 experimental)
Fanconi Anemia
48 drugs (27 approved, 21 experimental)
Li-Fraumeni Syndrome
2 approved drugs
Nijmegen Breakage Syndrome
1 experimental drug
Severe Combined Immunodeficiency
39 drugs (25 approved, 14 experimental)
Werner Syndrome
2 drugs (1 approved, 1 experimental)
Xeroderma Pigmentosum
3 approved drugs
Phase 4 Indicated Drugs (1)
Phase 3 Indicated Drugs (4)
Phase 2 Indicated Drugs (6)
Phase 1 Indicated Drugs (2)
Organization Involved with Phase 2 Indications (8)
Organization Involved with Phase 1 Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
